Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Salvat licenses tarafenacin to Kwang Dong Pharma for OAB in South Korea

Nov. 19, 2010

Orally disintegrating imidafenacin tablet approved in Japan for overactive bladder

Nov. 18, 2010

First patient treated in phase IIb AP-214 trial

Nov. 12, 2010

Watson Pharma plans to discontinue development of Uracyst

Nov. 11, 2010

Astellas Pharma's Vesicare OD approved in Japan for overactive bladder

Oct. 28, 2010

Keryx completes enrollment in short-term phase III efficacy study of Zerenex

Oct. 28, 2010

Two doses of Duromist oral spray show bioequivalence to Viagra tablet

Oct. 20, 2010

Amgen reviews TREAT data and proposes updates to ESA labeling

Oct. 19, 2010

Pharmalink obtains FDA orphan drug designation for PL-56

Oct. 14, 2010

Auxilium begins phase III Xiaflex studies in Peyronie's disease

Oct. 13, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...